Los Angeles Capital Management LLC Makes New 542,000 Investment in Entrada Therapeutics, Inc. - MarketBeat

TRDA Stock  USD 19.89  0.06  0.30%   
About 66% of Entrada Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Entrada Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Entrada Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Entrada Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
Los Angeles Capital Management LLC Makes New 542,000 Investment in Entrada Therapeutics, Inc. MarketBeat

Read at news.google.com
Google News at Macroaxis
  

Entrada Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Entrada Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Entrada Therapeutics Fundamental Analysis

We analyze Entrada Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Entrada Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Entrada Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Book Value Per Share

Book Value Per Share Comparative Analysis

Entrada Therapeutics is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Entrada Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Entrada Therapeutics stock to make a market-neutral strategy. Peer analysis of Entrada Therapeutics could also be used in its relative valuation, which is a method of valuing Entrada Therapeutics by comparing valuation metrics with similar companies.

Peers

Entrada Therapeutics Related Equities

GLUEMonte Rosa   13.72   
0%
100.0%
OPTOpthea   10.81   
0%
78.0%
VIGLVigil Neuroscience   7.39   
0%
53.0%
RLYBRallybio Corp   6.36   
0%
46.0%
CGEMCullinan Oncology   2.75   
0%
20.0%
EWTXEdgewise Therapeutics   2.48   
0%
18.0%
CNTACentessa Pharmaceuticals   1.76   
0%
12.0%
PMVPPmv Pharmaceuticals   1.25   
0%
9.0%
MOLNMolecular Partners   0.17   
1.0%
0%
CRNXCrinetics Pharmaceuticals   0.81   
5.0%
0%
PEPGPepGen   0.98   
7.0%
0%
ELYMEliem Therapeutics   1.30   
9.0%
0%
IRONDisc Medicine   1.70   
12.0%
0%
TYRATyra Biosciences   2.00   
14.0%
0%
PHVSPharvaris   2.06   
15.0%
0%
THRDThird Harmonic   2.67   
19.0%
0%
GNTAGenenta Science   3.35   
24.0%
0%
LRMRLarimar Therapeutics   4.67   
34.0%
0%

Complementary Tools for Entrada Stock analysis

When running Entrada Therapeutics' price analysis, check to measure Entrada Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entrada Therapeutics is operating at the current time. Most of Entrada Therapeutics' value examination focuses on studying past and present price action to predict the probability of Entrada Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entrada Therapeutics' price. Additionally, you may evaluate how the addition of Entrada Therapeutics to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Transaction History
View history of all your transactions and understand their impact on performance
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities